ArticleJournal of immunology research2018

Selective Immunomodulation of Inflammatory Pathways in Keratinocytes by the Janus Kinase (JAK) Inhibitor Tofacitinib: Implications for the Employment of JAK-Targeting Drugs in Psoriasis.

Martina Morelli et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.